Yahoo
LSE - Delayed Quote GBp

Coiled Therapeutics plc (COIL.L)

6.90 0.00 (0.00%)
At close: October 30 at 9:57:50 AM GMT
Chart Range Bar
Loading chart for COIL.L
  • Previous Close 6.90
  • Open 6.83
  • Bid 6.80 x --
  • Ask 7.00 x --
  • Day's Range 6.83 - 6.83
  • 52 Week Range 0.95 - 30.00
  • Volume 32,712
  • Avg. Volume 271,880
  • Market Cap (intraday) 29.449M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.20
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 21.63

Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company's lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials. The company is based in London, United Kingdom.

coiledplc.com

--

Full Time Employees

--

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

COIL.L
44.80%
FTSE 100 (^FTSE)
8.04%

1-Year Return

COIL.L
63.68%
FTSE 100 (^FTSE)
9.94%

3-Year Return

COIL.L
89.96%
FTSE 100 (^FTSE)
46.43%

5-Year Return

COIL.L
94.48%
FTSE 100 (^FTSE)
48.25%

Analyst Insights

View More

Analyst Price Targets

21.63
21.63 Average
6.90 Current
21.63 High

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -0.20

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: